Home Improvement
Compare Stocks
5 / 10Stock Comparison
PFAI vs CLOV vs ACMR vs BBAI vs SOUN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Semiconductors
Information Technology Services
Software - Application
PFAI vs CLOV vs ACMR vs BBAI vs SOUN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Home Improvement | Medical - Healthcare Plans | Semiconductors | Information Technology Services | Software - Application |
| Market Cap | $31M | $1.44B | $3.92B | $19.73B | $4.10B |
| Revenue (TTM) | $3M | $2.21B | $901M | $127M | $169M |
| Net Income (TTM) | $286K | $-57M | $94M | $-289M | $-14M |
| Gross Margin | 47.3% | 42.5% | 44.4% | 25.8% | 42.4% |
| Operating Margin | 18.7% | -2.6% | 12.1% | -68.3% | -13.8% |
| Forward P/E | 190.5x | 65.9x | 29.7x | — | — |
| Total Debt | $163K | $0.00 | $303M | $24M | $4M |
| Cash & Equiv. | $686K | $78M | $766M | $87M | $248M |
PFAI vs CLOV vs ACMR vs BBAI vs SOUN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 25 | May 26 | Return |
|---|---|---|---|
| Pinnacle Food Group… (PFAI) | 100 | 126.4 | +26.4% |
| Clover Health Inves… (CLOV) | 100 | 82.9 | -17.1% |
| ACM Research, Inc. (ACMR) | 100 | 304.1 | +204.1% |
| BigBear.ai Holdings… (BBAI) | 100 | 122.3 | +22.3% |
| SoundHound AI, Inc. (SOUN) | 100 | 103.7 | +3.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PFAI vs CLOV vs ACMR vs BBAI vs SOUN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PFAI is the #2 pick in this set and the best alternative if stability and efficiency is your priority.
- Beta 0.53 vs SOUN's 3.58
- 6.1% ROA vs BBAI's -35.3%
CLOV lags the leaders in this set but could rank higher in a more targeted comparison.
ACMR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 3 yrs, beta 3.24, yield 0.2%
- 30.7% 10Y total return vs SOUN's 28.4%
- Lower volatility, beta 3.24, Low D/E 15.7%, current ratio 3.27x
- Beta 3.24, yield 0.2%, current ratio 3.27x
Among these 5 stocks, BBAI doesn't own a clear edge in any measured category.
SOUN ranks third and is worth considering specifically for growth exposure.
- Rev growth 99.4%, EPS growth 96.7%, 3Y rev CAGR 75.7%
- 99.4% revenue growth vs BBAI's -19.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 99.4% revenue growth vs BBAI's -19.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 10.4% margin vs BBAI's -226.7% | |
| Stability / Safety | Beta 0.53 vs SOUN's 3.58 | |
| Dividends | 0.2% yield; 3-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +195.6% vs CLOV's -25.2% | |
| Efficiency (ROA) | 6.1% ROA vs BBAI's -35.3% |
PFAI vs CLOV vs ACMR vs BBAI vs SOUN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PFAI vs CLOV vs ACMR vs BBAI vs SOUN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ACMR leads in 3 of 6 categories
PFAI leads 1 • CLOV leads 0 • BBAI leads 0 • SOUN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — PFAI and CLOV each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CLOV is the larger business by revenue, generating $2.2B annually — 672.1x PFAI's $3M. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to BBAI's -2.3%. On growth, CLOV holds the edge at +62.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3M | $2.2B | $901M | $127M | $169M |
| EBITDAEarnings before interest/tax | — | -$55M | $126M | -$75M | $52M |
| Net IncomeAfter-tax profit | — | -$57M | $94M | -$289M | -$14M |
| Free Cash FlowCash after capex | — | $55M | -$69M | -$56M | -$77M |
| Gross MarginGross profit ÷ Revenue | +47.3% | +42.5% | +44.4% | +25.8% | +42.4% |
| Operating MarginEBIT ÷ Revenue | +18.7% | -2.6% | +12.1% | -68.3% | -13.8% |
| Net MarginNet income ÷ Revenue | +8.7% | -2.6% | +10.4% | -2.3% | -8.3% |
| FCF MarginFCF ÷ Revenue | -27.2% | +2.5% | -7.6% | -44.3% | -45.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +62.0% | +9.4% | -0.9% | +59.4% |
| EPS Growth (YoY)Latest quarter vs prior year | — | — | -76.1% | +52.0% | +113.9% |
Valuation Metrics
ACMR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 43.2x trailing earnings, ACMR trades at a 77% valuation discount to PFAI's 190.5x P/E. On an enterprise value basis, ACMR's 27.5x EV/EBITDA is more attractive than SOUN's 355.5x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $31M | $1.4B | $3.9B | $19.7B | $4.1B |
| Enterprise ValueMkt cap + debt − cash | $30M | $1.4B | $3.5B | $19.7B | $3.9B |
| Trailing P/EPrice ÷ TTM EPS | 190.52x | -16.59x | 43.21x | -5.09x | -278.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 65.89x | 29.68x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.22x | — | — |
| EV / EBITDAEnterprise value multiple | 31.75x | — | 27.49x | — | 355.51x |
| Price / SalesMarket cap ÷ Revenue | 9.40x | 0.75x | 4.35x | 154.51x | 24.30x |
| Price / BookPrice ÷ Book value/share | 85.30x | 4.72x | 2.06x | 24.45x | 8.42x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Profitability & Efficiency
PFAI leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
PFAI delivers a 61.3% return on equity — every $100 of shareholder capital generates $61 in annual profit, vs $-51 for BBAI. SOUN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PFAI's 0.35x. On the Piotroski fundamental quality scale (0–9), PFAI scores 6/9 vs ACMR's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +61.3% | -17.1% | +6.1% | -50.7% | -3.5% |
| ROA (TTM)Return on assets | +6.1% | -9.6% | +3.9% | -35.3% | -2.2% |
| ROICReturn on invested capital | — | -34.0% | +7.0% | -19.5% | -16.8% |
| ROCEReturn on capital employed | +34.7% | -24.5% | +6.6% | -19.6% | -4.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 2 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.35x | — | 0.16x | 0.04x | 0.01x |
| Net DebtTotal debt minus cash | -$523,124 | -$78M | -$463M | -$63M | -$244M |
| Cash & Equiv.Liquid assets | $685,796 | $78M | $766M | $87M | $248M |
| Total DebtShort + long-term debt | $162,672 | $0 | $303M | $24M | $4M |
| Interest CoverageEBIT ÷ Interest expense | — | — | 20.44x | -18.17x | -12.84x |
Total Returns (Dividends Reinvested)
ACMR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACMR five years ago would be worth $23,344 today (with dividends reinvested), compared to $3,271 for CLOV. Over the past 12 months, ACMR leads with a +195.6% total return vs CLOV's -25.2%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs PFAI's 0.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +85.3% | +17.0% | +31.9% | -28.6% | -9.2% |
| 1-Year ReturnPast 12 months | +26.8% | -25.2% | +195.6% | +36.7% | +5.0% |
| 3-Year ReturnCumulative with dividends | +0.5% | +221.7% | +487.9% | +49.5% | +254.0% |
| 5-Year ReturnCumulative with dividends | +0.5% | -67.3% | +133.4% | -56.9% | +28.4% |
| 10-Year ReturnCumulative with dividends | +0.5% | -72.4% | +3065.8% | -57.6% | +28.4% |
| CAGR (3Y)Annualised 3-year return | +0.2% | +47.6% | +80.5% | +14.3% | +52.4% |
Risk & Volatility
Evenly matched — PFAI and ACMR each lead in 1 of 2 comparable metrics.
Risk & Volatility
PFAI is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than SOUN's 3.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACMR currently trades 82.6% from its 52-week high vs SOUN's 43.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.53x | 1.22x | 3.24x | 3.31x | 3.58x |
| 52-Week HighHighest price in past year | $4.93 | $3.92 | $71.65 | $9.39 | $22.17 |
| 52-Week LowLowest price in past year | $1.30 | $1.58 | $19.26 | $2.96 | $5.83 |
| % of 52W HighCurrent price vs 52-week peak | +81.5% | +71.9% | +82.6% | +44.4% | +43.4% |
| RSI (14)Momentum oscillator 0–100 | 55.6 | 69.5 | 60.7 | 63.3 | 64.6 |
| Avg Volume (50D)Average daily shares traded | 8K | 5.6M | 1.2M | 34.6M | 27.9M |
Analyst Outlook
ACMR leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CLOV as "Hold", ACMR as "Buy", BBAI as "Hold", SOUN as "Buy". Consensus price targets imply 43.9% upside for BBAI (target: $6) vs -32.4% for ACMR (target: $40). ACMR is the only dividend payer here at 0.19% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $3.33 | $40.00 | $6.00 | $13.33 |
| # AnalystsCovering analysts | — | 9 | 10 | 4 | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.2% | — | — |
| Dividend StreakConsecutive years of raises | — | — | 3 | 2 | — |
| Dividend / ShareAnnual DPS | — | — | $0.11 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.8% | +0.2% | 0.0% | 0.0% |
ACMR leads in 3 of 6 categories (Valuation Metrics, Total Returns). PFAI leads in 1 (Profitability & Efficiency). 2 tied.
PFAI vs CLOV vs ACMR vs BBAI vs SOUN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PFAI or CLOV or ACMR or BBAI or SOUN a better buy right now?
For growth investors, SoundHound AI, Inc.
(SOUN) is the stronger pick with 99. 4% revenue growth year-over-year, versus -19. 3% for BigBear. ai Holdings, Inc. (BBAI). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PFAI or CLOV or ACMR or BBAI or SOUN?
On trailing P/E, ACM Research, Inc.
(ACMR) is the cheapest at 43. 2x versus Pinnacle Food Group Limited Class A Common Shares at 190. 5x. On forward P/E, ACM Research, Inc. is actually cheaper at 29. 7x.
03Which is the better long-term investment — PFAI or CLOV or ACMR or BBAI or SOUN?
Over the past 5 years, ACM Research, Inc.
(ACMR) delivered a total return of +133. 4%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PFAI or CLOV or ACMR or BBAI or SOUN?
By beta (market sensitivity over 5 years), Pinnacle Food Group Limited Class A Common Shares (PFAI) is the lower-risk stock at 0.
53β versus SoundHound AI, Inc. 's 3. 58β — meaning SOUN is approximately 573% more volatile than PFAI relative to the S&P 500. On balance sheet safety, SoundHound AI, Inc. (SOUN) carries a lower debt/equity ratio of 1% versus 35% for Pinnacle Food Group Limited Class A Common Shares — giving it more financial flexibility in a downturn.
05Which is growing faster — PFAI or CLOV or ACMR or BBAI or SOUN?
By revenue growth (latest reported year), SoundHound AI, Inc.
(SOUN) is pulling ahead at 99. 4% versus -19. 3% for BigBear. ai Holdings, Inc. (BBAI). On earnings-per-share growth, the picture is similar: SoundHound AI, Inc. grew EPS 96. 7% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, SOUN leads at 75. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PFAI or CLOV or ACMR or BBAI or SOUN?
ACM Research, Inc.
(ACMR) is the more profitable company, earning 10. 4% net margin versus -230. 2% for BigBear. ai Holdings, Inc. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFAI leads at 18. 7% versus -65. 3% for BBAI. At the gross margin level — before operating expenses — PFAI leads at 47. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PFAI or CLOV or ACMR or BBAI or SOUN more undervalued right now?
On forward earnings alone, ACM Research, Inc.
(ACMR) trades at 29. 7x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 36. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BBAI: 43. 9% to $6. 00.
08Which pays a better dividend — PFAI or CLOV or ACMR or BBAI or SOUN?
In this comparison, ACMR (0.
2% yield) pays a dividend. PFAI, CLOV, BBAI, SOUN do not pay a meaningful dividend and should not be held primarily for income.
09Is PFAI or CLOV or ACMR or BBAI or SOUN better for a retirement portfolio?
For long-horizon retirement investors, Pinnacle Food Group Limited Class A Common Shares (PFAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
53)). BigBear. ai Holdings, Inc. (BBAI) carries a higher beta of 3. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PFAI: +0. 5%, BBAI: -57. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PFAI and CLOV and ACMR and BBAI and SOUN?
These companies operate in different sectors (PFAI (Consumer Cyclical) and CLOV (Healthcare) and ACMR (Technology) and BBAI (Technology) and SOUN (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PFAI is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; BBAI is a mid-cap quality compounder stock; SOUN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.